ValuEngine lowered shares of Akebia Therapeutics (NASDAQ:AKBA) from a hold rating to a sell rating in a report released on Tuesday morning.

Several other equities research analysts have also weighed in on AKBA. Zacks Investment Research upgraded shares of Akebia Therapeutics from a hold rating to a buy rating and set a $17.00 target price on the stock in a report on Monday, November 13th. HC Wainwright reiterated a buy rating and issued a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, November 15th. BTIG Research started coverage on shares of Akebia Therapeutics in a report on Thursday, December 7th. They issued a buy rating and a $30.00 target price on the stock. Piper Jaffray Companies started coverage on shares of Akebia Therapeutics in a report on Monday, December 18th. They issued an overweight rating and a $26.00 target price on the stock. Finally, Mizuho reiterated a buy rating and issued a $24.00 target price on shares of Akebia Therapeutics in a report on Tuesday, February 13th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $22.20.

How to Become a New Pot Stock Millionaire

Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at $12.59 on Tuesday. The firm has a market cap of $571.45, a price-to-earnings ratio of -3.98 and a beta of 0.80. Akebia Therapeutics has a twelve month low of $8.69 and a twelve month high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Monday, March 12th. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.61. The company had revenue of $87.32 million for the quarter, compared to analyst estimates of $66.00 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. equities research analysts expect that Akebia Therapeutics will post -2.25 EPS for the current fiscal year.

Several large investors have recently modified their holdings of AKBA. Macquarie Group Ltd. acquired a new stake in shares of Akebia Therapeutics during the third quarter worth $183,000. Teacher Retirement System of Texas acquired a new stake in shares of Akebia Therapeutics during the fourth quarter worth $188,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Akebia Therapeutics during the third quarter worth $200,000. Caxton Associates LP acquired a new stake in shares of Akebia Therapeutics during the third quarter worth $246,000. Finally, Voya Investment Management LLC raised its holdings in shares of Akebia Therapeutics by 11.7% during the second quarter. Voya Investment Management LLC now owns 18,454 shares of the biopharmaceutical company’s stock worth $265,000 after acquiring an additional 1,933 shares during the period. Institutional investors and hedge funds own 71.23% of the company’s stock.

WARNING: “Akebia Therapeutics (AKBA) Downgraded by ValuEngine” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/03/14/akebia-therapeutics-akba-downgraded-by-valuengine.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.